ACAAI 2018 Poster: Phase 1/1b study of inhaled formulation in healthy volunteers & asthmatics

PUR1900 is an iSPERSE™ formulation incorporating a large, complex anti-fungal compound that can be administered at high therapeutic dose to the lung while minimizing systemic side effects.

This Phase 1/1b study was conducted to evaluate the safety, tolerability and pharmacokinetics of PUR1900 in healthy volunteers and asthmatics. Request a copy of our poster now.